drugset
drugset / Trial / NCT04321252

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

NCT04321252 ↗

Phase 1 Completed 57 enrolled Novartis Pharmaceuticals Wellcome Trust · collab
RandomizedSequentialDouble-blindOther

Summary

This was a randomized, subject and investigator-blinded, placebo-controlled, single and multiple ascending intravenous (iv) dose study in healthy subjects to assess the safety and tolerability of KAE609 given in the vein.

Timeline

Start
2020-07-22
Primary completion
2020-11-10
Completion
2020-11-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject cipargamin Small molecule 10.5 mg Intravenous
Subject cipargamin Small molecule 30 mg Intravenous
Subject cipargamin Small molecule 60 mg Intravenous
Subject cipargamin Small molecule 75 mg Intravenous
Subject cipargamin Small molecule 120 mg Intravenous
Subject cipargamin Small molecule 210 mg Intravenous

Indications

malaria